1. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer
- Author
-
Holland, Levi, Bhanvadia, Raj, Ibeziako, Nathanaelle, Taylor, Jacob, Gerlt, Deitrich, Chaplin, Iftach, Bagrodia, Aditya, Desai, Neil, Gaston, Kris, Lotan, Yair, Margulis, Vitaly, Zhang, Tian, Cole, Suzanne, and Woldu, Solomon
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunotherapy ,Rare Diseases ,Urologic Diseases ,Health Disparities ,Cancer ,Kidney Disease ,Minority Health ,Good Health and Well Being ,Humans ,Male ,Female ,Urinary Bladder Neoplasms ,Aged ,Middle Aged ,Kidney Neoplasms ,Healthcare Disparities ,Socioeconomic Factors ,Carcinoma ,Renal Cell ,United States ,Carcinoma ,Transitional Cell ,Sociodemographic Factors ,Neoplasm Staging ,Renal cell carcinoma ,Kidney cancer ,Bladder cancer ,Healthcare disparities ,Socioeconomic factors ,Urology & Nephrology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
ObjectivesImmunotherapy (IO) drugs have been increasingly utilized in locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma of the bladder (UC). Multiple trials have demonstrated clear survival benefit, however, there are often barriers to access for these advanced therapies which has been demonstrated in other non-urologic malignancies. The goal of this study was to assess socioeconomic and demographic factors associated with the receipt of IO for advanced ccRCC and UC.Materials and methodsWe queried the National Cancer Database (NCDB) for patients with stage IV ccRCC and UC. The study period was 2015 to 2020 for ccRCC (FDA approval date of IO) and 2017 to 2020 for UC (FDA approval date of broadened indication for IO, initial limited approval in 2016). The primary outcome of interest was receipt of IO therapy using multivariable logistic regression, adjusting for relevant socioeconomic and demographic variables.ResultsWe identified 15,926 patients with stage IV ccRCC and 10,380 patients with stage IV UC of which 5,419 (34.0%) and 2,231 (21.5%) received IO therapy, respectively. IO utilization increased with each successive year. In both malignancies, treatment at a non-academic facility, education level, income, and insurance were independently associated with IO utilization. For ccRCC, black (OR = 0.77, 95% CI, 0.64-0.93, P = 0.009) and Hispanic race (OR = 0.73, 95% CI, 0.61-0.86, P = 0.006) were each associated with decreased IO utilization but there were no independent associations between race and receipt of IO in patients with UC.ConclusionsIn the era of FDA-approved IO therapy for advanced ccRCC and UC, this national cohort analysis suggests that IO utilization is increasing over time, but significant disparities exist based on income, education, and insurance status in both malignancies. Additionally, patients treated at non-academic facilities were less likely to receive IO therapy for these specific genitourinary malignancies. In ccRCC, additional disparities were seen black and Hispanic races which each were associated with lower odds of IO receipt. Identifying strategies to mitigate these differences and provide equitable access to IO therapy is of imperative need.
- Published
- 2024